title: Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study.
abstract: OBJECTIVE
  To assess the effect of tibolone on markers of vascular risk in postmenopausal women who were receiving hemodialysis.
  
  
  METHODS
  One-year open-label study.
  
  
  METHODS
  "Zvezdara" University Medical Center, Belgrade, Serbia.
  
  
  METHODS
  Twenty-eight postmenopausal women undergoing chronic hemodialysis.
  
  
  METHODS
  Fifteen women received tibolone 2.5 mg three times per week; 13 other women served as controls.
  
  
  METHODS
  Mean arterial pressure and weight were measured at baseline and at 6 and 12 months, and blood was collected for insulin, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, lipoprotein(a), high-sensitivity C-reactive protein (hs-CRP), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and markers of renal function.
  
  
  RESULTS
  Mean arterial pressure fell in the tibolone but not in the control group at 6 and 12 months versus baseline (mean [SD]: 93 [15] vs. 105 [11] mmHg and 94 [10] vs. 105 [11] mmHg, respectively). Weight, insulin, lipids, lipoprotein(a), hs-CRP, ET-1, VEGF, and renal function remained unchanged within each group, but high-density lipoprotein concentrations fell in the tibolone group after 12 months (1.2 [0.3] vs. 1.6 [0.6] mmol/L).
  
  
  CONCLUSIONS
  The effects of tibolone on markers of vascular risk in postmenopausal women who are receiving hemodialysis and healthy women appear to differ. This should be taken into account when tailoring menopausal therapies to the specific requirements of each individual.
authors.affiliation: Department of Medicine, Royal Free and University College Medical School, London, United Kingdom.
authors.forename: Julia E
authors.initials: JE
authors.lastname: Ostberg
authors.forename: Tatjana
authors.initials: T
authors.lastname: Damjanovic
authors.forename: Nada
authors.initials: N
authors.lastname: Dimkovic
authors.forename: Dominic
authors.initials: D
authors.lastname: Byrne
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
authors.forename: Gordana M
authors.initials: GM
authors.lastname: Prelevic
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008055:Lipids / Q000097:blood; D017270:Lipoprotein(a) / Q000097:blood; D008075:Lipoproteins, HDL / Q000037:antagonists & inhibitors / Q000097:blood; D009652:Norpregnenes / Q000627:therapeutic use*; D010865:Pilot Projects; D017698:Postmenopause; D006435:Renal Dialysis; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D007328:Insulin; D008055:Lipids; D017270:Lipoprotein(a); D008075:Lipoproteins, HDL; D009652:Norpregnenes; D042461:Vascular Endothelial Growth Factor A; D002097:C-Reactive Protein; C027385:tibolone